PDCD1 and cancer: Because MEK inhibition also resulted in immune activation in select patients with non-RRD cancers, (39–41), we hypothesized that MEK inhibitors could be effective in RRD-HGG harboring RAS/MAPK variants and, in addition, contribute to immune synergism to drive the responses in patients with RRD-HGG continuing on anti–PD-1.